TuisAMGN • NASDAQ
add
Amgen Inc
Vorige sluiting
$277,49
Dagwisseling
$273,13 - $280,54
Jaarwisseling
$253,30 - $346,85
Markkapitalisasie
150,75 mjd USD
Gemiddelde volume
2,96 m
P/V-verhouding
25,59
Dividend-opbrengs
3,40%
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 8,15 mjd | 9,43% |
Bedryfskoste | 3,20 mjd | 0,47% |
Netto inkomste | 1,73 mjd | 1 630,97% |
Netto winsgrens | 21,23 | 1 496,71% |
Wins per aandeel | 4,90 | 23,74% |
EBITDA | 3,52 mjd | 19,29% |
Effektiewe belastingkoers | 12,32% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 8,81 mjd | -9,25% |
Totale bates | 89,37 mjd | -3,89% |
Totale aanspreeklikheid | 83,16 mjd | -5,45% |
Totale ekwiteit | 6,21 mjd | — |
Uitstaande aandele | 537,71 m | — |
Prys om te bespreek | 24,05 | — |
Opbrengs op bates | 6,46% | — |
Opbrengs op kapitaal | 8,98% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,73 mjd | 1 630,97% |
Kontant van bedrywe | 1,39 mjd | 101,89% |
Kontant van beleggings | -447,00 m | -105,99% |
Kontant van finansiering | -4,11 mjd | -140,46% |
Netto kontantverandering | -3,16 mjd | -155,91% |
Beskikbare kontantvloei | 1,21 mjd | -34,48% |
Meer oor
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp Wikipedia
Gestig
08 Apr. 1980
Webwerf
Werknemers
28 000
